Grifols Share Price - GRFS

20.02
0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
20.02
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Basic
Monthly Subscription
for only
$33.03
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
$67.09
VAT not included
Company Name Stock Ticker Symbol Market Type
Grifols SA GRFS NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.27 1.37% 20.02 19.84 20.23 20.18 19.75 20:00:00
Bid Price Ask Price Spread Spread % News
17.50 23.00 5.50 23.91% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume
6,798 1,097,228  19.99  21,937,270 796,930
Last Trade Time Type Quantity Stock Price Currency
16:24:32 formt 213,400  20.02 USD

Grifols Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 13.70B 684.14M 684.14M  5.72B  806.16M 1.02 17.50
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  0.40 2.00% - -

more financials information »

News Grifols

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

GRFS Historical

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Grifols SA is a vertically integrated plasma derivative producer in Spain. It collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's bioscience business contributed 78% of sales in 2018. Grifols also has smaller segments including diagnostics, hospital supplies, and biosupplies. Diagnostics is now roughly 14% of revenue following the Novartis and Hologic deals.


Your Recent History
NASDAQ
GRFS
Grifols
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.